Expansion of the genetic and phenotypic spectrum of hereditary spastic paraplegia caused by ABHD16A gene variants: an integrated analysis based on novel variants and literature review

Read full text
Authors: Manling He, Qiang Zhang, Shaoke Chen, Chuan Li, Bobo Xie, Qingxiu Zhao, Yiyun Henry Huang, Xin Fan
Cited by: 1
References: 22

Abstract

Background Hereditary spastic paraplegia (HSP) is a clinically and genetically heterogeneous neurodegenerative disorder. Biallelic pathogenic variants in ABHD16A have recently been linked to a neurodevelopmental phenotype featuring early-onset spasticity and global developmental delay. Objective To further define the clinical and genetic spectrum of ABHD16A -associated disease through the characterization of a novel pediatric case and an updated literature review. Methods We evaluated a child presenting with global developmental delay and progressive spastic paraplegia. Whole-exome sequencing (WES) was performed, and candidate variants were validated by Sanger sequencing. Clinical features were documented prospectively, and a systematic review of published cases was conducted to assess phenotypic patterns and genotype–phenotype relationships. Results Consistent with prior reports, the core features of ABHD16A -related disease include global developmental delay, intellectual disability, and spastic paraplegia, often with early onset. In our patient, tandem mass spectrometry revealed elevated long-chain acylcarnitines (C16, C18:1, C18:2)—a metabolic abnormality not previously described in this condition. WES identified two novel compound heterozygous frameshift variants in ABHD16A : c.119delA (p.His40Leufs49) and c.559_562del (p.Pro187Cysfs29), both confirmed by Sanger sequencing and classified as pathogenic (ACMG criteria: PVS1, PM2, PM3, PP1). Our literature review identified 17 additional individuals from 9 families, enabling a refined clinical delineation: most patients exhibited motor and speech delay, axial hypotonia evolving into spasticity, and variable degrees of cognitive impairment. Conclusions To our knowledge, this is the first reported case of ABHD16A -related neurodevelopmental disorder in a Chinese patient. We provide a detailed phenotypic characterization and an updated review of the published literature to support clinical recognition and genetic diagnosis of this emerging condition.

Fields of Study & Subjects

Hereditary Neurological Disorders Botulinum Toxin and Related Neurological Disorders Neurological diseases and metabolism

Publication details

Journal / source
Frontiers in Pediatrics
Publisher
Frontiers Media SA
Volume
13
Pages
1724515–1724515
Publication date
5 January 2026
Language
EN